U.S. Based Medicinova Aims To Boost Efficiency In Japanese Drug Development
This article was originally published in PharmAsia News
Executive Summary
California-based pharmaceutical venture company Medicinova plans to buy preclinical drug candidates in Japan that have been cleared for the clinic, and conduct more efficient clinical trials in Europe and the U.S., Medicinova President Yuichi Iwaki said in an interview in Mainichi News. Medicinova will then sell the products after the trials. Currently, Medicinova is developing 10 drugs, including Kissei's bronchitis and acute asthma candidate MN-221 and Kyorin's multiple sclerosis treatment MN-166. (Click for more-Japanese language